AR
Data & Repro
armored-cart-design-agent
Design armored CAR-T cells with cytokine payloads and resistance mechanisms.
FreedomIntelligence/OpenClaw-Medical-SkillsView
Data & Repro
MY
myeloma-mrd-agent
Maintainer FreedomIntelligence · Last updated April 1, 2026
Multiple myeloma MRD assessment from flow cytometry and NGS data.
Original source
FreedomIntelligence/OpenClaw-Medical-Skills
https://github.com/FreedomIntelligence/OpenClaw-Medical-Skills/tree/main/skills/myeloma-mrd-agent
- Maintainer
- FreedomIntelligence
- License
- MIT
- Last updated
- April 1, 2026
Skill Snapshot
Key Details From SKILL.md
Key Notes
- The Myeloma MRD Agent provides comprehensive AI-driven minimal residual disease assessment for multiple myeloma. It integrates next-generation flow cytometry (NGF), NGS-based clonotype tracking, and mass spectrometry M-protein detection for ultra-sensitive MRD monitoring.
- When assessing MRD status in multiple myeloma patients post-treatment.
- To select optimal MRD testing modality (NGF vs NGS vs MS).
- For predicting progression-free survival based on MRD kinetics.
- When integrating MRD with other response criteria (IMWG).
Source Doc
Excerpt From SKILL.md
Core Capabilities
-
NGF Analysis: AI-enhanced next-generation flow cytometry for MRD detection at 10^-5 to 10^-6 sensitivity.
-
NGS Clonotype Tracking: Analyze IGH/IGK/IGL rearrangements for molecular MRD.
-
Mass Spectrometry: MALDI-TOF or LC-MS/MS for M-protein detection.
-
Multi-Modal Integration: Combine modalities for comprehensive MRD assessment.
-
Kinetic Modeling: Track MRD dynamics and predict outcomes.
-
Response Classification: Apply IMWG MRD criteria.
MRD Detection Methods
| Method | Sensitivity | Sample | Advantages |
|---|---|---|---|
| NGF (EuroFlow) | 10^-5 to 10^-6 | BM | Standardized, fast |
| NGS (clonoSEQ) | 10^-6 | BM | Ultra-sensitive |
| ASO-qPCR | 10^-5 | BM | Quantitative |
| PET-CT | N/A | Whole body | Extramedullary |
| MS (MALDI/LC-MS) | 10^-5 | Serum | Non-invasive |
IMWG MRD Response Criteria
| Category | Definition |
|---|---|
| MRD-negative (10^-5) | No clonal plasma cells by NGF or NGS at 10^-5 |
| MRD-negative (10^-6) | No clonal plasma cells at 10^-6 sensitivity |
| Sustained MRD-neg | MRD-neg confirmed ≥1 year apart |
| Flow MRD-neg | NGF negative, sensitivity ≥10^-5 |
| Sequencing MRD-neg | NGS negative, sensitivity ≥10^-5 |
Use cases
- When assessing MRD status in multiple myeloma patients post-treatment.
- To select optimal MRD testing modality (NGF vs NGS vs MS).
- For predicting progression-free survival based on MRD kinetics.
- When integrating MRD with other response criteria (IMWG).
Not for
- Do not rely on this catalog entry alone for installation or maintenance details.
Upstream Related Skills
- Flow_Cytometry_AI - For general flow analysis
- Multiple_Myeloma_AI - For disease-specific analysis
- Liquid_Biopsy_Analytics_Agent - For ctDNA approaches
Related skills
Related skills
AR
Data & Repro
arxiv-search
Search arXiv physics, math, and computer science preprints using natural language queries. Powered by Valyu semantic search.
FreedomIntelligence/OpenClaw-Medical-SkillsView
AU
Data & Repro
autonomous-oncology-agent
Autonomous oncology research agent: literature mining, trial matching, biomarker analysis, and treatment hypothesis generation.
FreedomIntelligence/OpenClaw-Medical-SkillsView
BI
Data & Repro
bio-cfdna-preprocessing
Preprocesses cell-free DNA sequencing data including adapter trimming, alignment optimized for short fragments, and UMI-aware duplicate remo…
FreedomIntelligence/OpenClaw-Medical-SkillsView